A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naive Patients With Type 2 Diabetes (T2DM).

Trial Profile

A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naive Patients With Type 2 Diabetes (T2DM).

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Exenatide (Primary) ; Liraglutide (Primary) ; Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms SAFEGUARD
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Dec 2016 Primary endpoint has been met. (Changes from baseline following 12-week treatment with DPP-4i Sitagliptin or GLP-1RA liraglutide (long-term effects) on pancreatic exocrine function (chymotrypsin)) as per article published in the Diabetes Care.
    • 20 Dec 2016 Primary endpoint has not been met. (Changes from baseline following 12-week treatment with GLP-1RA liraglutide or DPP-4i Sitagliptin (long-term effects) on pancreatic exocrine function, (lipase activity measured as cumulative13C recovery)) as per article published in the Diabetes Care.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top